MNCs Against Pricing Structure Of National Basic Medicine System
This article was originally published in PharmAsia News
Executive Summary
R&D-based Pharmaceutical Association Committee, multinational pharma's mouthpiece in China, recently disclosed its proposal for the national health care reform plan opinion draft. RDPAC considers the plan, which designates certain enterprises to produce and market basic medicine, to go against the country's anti-monopoly principles. Local pharmaceutical industry associations hold the same view (PharmAsia News, Oct. 20, 2008). (Click here for more - Chinese language)